Skip to main content
Clinical Trials/EUCTR2010-023979-25-DK
EUCTR2010-023979-25-DK
Active, not recruiting
Not Applicable

Role of renal and systemic vascular resistance for progression of chronic kidney disease - RenVas

Department of Nephrology0 sites110 target enrollmentDecember 15, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Nephrology
Enrollment
110
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 15, 2010
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • CKD grade 3\-4
  • Hypertension (Blood pressure \> 130/80 measured 24 h ambulatory)
  • Age\> 18 years
  • Fertile women: Must have safe contraception
  • Informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Claustrophobia in a degree which makes MRI impossible
  • Ultrasound verified polycystic kidney disease
  • Pregnancy or wish to be pregnant
  • Contraindications to MRI (Pacemaker, metal implants incompatible with MRI)
  • Allergy to the medicine used in the trail
  • Blood pressure blow 130/80 (24 h ambulatory) without antihypertensive drugs
  • Blood pressure over 130/80 (24h ambulatory) while treatmented with maximum dose of beta\-blocker, ACEi and CCB simultaneously.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
The clinical efficacy of Surgical pleth index (SPI) and analgesia nociception index (ANI)Diseases of the digestive system
KCT0008473Samsung Medical Center47
Recruiting
Phase 3
Renal resistive index guided renal responsivenessPostoperative critically ill adult patients with oliguria
TCTR20210315005Ramathibodi Hospital, Mahidol University48
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2014-005033-31-FRAddmedica S.A.S
Not yet recruiting
Not Applicable
Role of ultrasound derived kidney index and urine and serum biomarkers in determining the type of kidney injury in patients with liver diseaseHealth Condition 1: N179- Acute kidney failure, unspecifiedHealth Condition 2: K746- Other and unspecified cirrhosis ofliver
CTRI/2020/09/027816Dr Ajay Kumar
Completed
Not Applicable
Influence of renal dysfunction on the outcomes of hepatectomy for hepatocellular carcinoma
JPRN-UMIN000041749Hiroshima University238